ALNYLAM PHARMACEUTICALS, INC.

Form 4

November 13, 2015

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB 3235-0287 Number:

January 31,

Expires:

2005

0.5

Estimated average burden hours per

response...

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Addres STARR KEVIN (Last)	P (First)	ng Person * (Middle)	2. Issuer Name and Ticker or Trading Symbol ALNYLAM PHARMACEUTICALS, INC. [ALNY] 3. Date of Earliest Transaction (Month/Day/Year) 11/11/2015	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below)
CAMBRIDGE,	(Street) MA 02142		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person

(City)	(State)	(Zip) Tal	Derivative	Secu	rities Acquire	ed, Disposed of, o	or Beneficially	Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securities Acquired (A) or nDisposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. 7. Nature of Ownership Indirect Form: Beneficial Direct (D) Ownership or Indirect (Instr. 4) (I) (Instr. 4)		
Common Stock	11/11/2015		M(1)	25,000	A	\$ 9.3	25,000	D	
Common Stock	11/11/2015		M(1)	12,500	A	\$ 11.33	37,500	D	
Common Stock	11/11/2015		S <u>(1)</u>	2,274	D	\$ 105.3117 (2)	35,226	D	
Common Stock	11/11/2015		S <u>(1)</u>	4,027	D	\$ 106.4611 (3)	31,199	D	

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Common Stock	11/11/2015	S <u>(1)</u>	12,606	D	\$ 107.3901 (4)	18,593	D
Common Stock	11/11/2015	S <u>(1)</u>	15,499	D	\$ 108.2258 (5)	3,094	D
Common Stock	11/11/2015	S <u>(1)</u>	3,094	D	\$ 109.1417 <u>(6)</u>	0	D
Common Stock	11/12/2015	M(1)	12,500	A	\$ 11.33	12,500	D
Common Stock	11/12/2015	M(1)	25,000	A	\$ 15.82	37,500	D
Common Stock	11/12/2015	S <u>(1)</u>	35,400	D	\$ 100.0135 (7)	2,100	D
Common Stock	11/12/2015	S <u>(1)</u>	1,200	D	\$ 101.5825 (8)	900	D
Common Stock	11/12/2015	S <u>(1)</u>	900	D	\$ 103.0089 (9)	0	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

buy)

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amour or Number of Sha
Stock Option (right to	\$ 11.33	11/11/2015		M(1)		12,500	06/21/2013(10)	06/21/2022	Common Stock	12,50

(9-02)

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Stock Option (right to buy)	\$ 11.33	11/12/2015	M(1)	12,500	06/21/2013(10)	06/21/2022	Common Stock	12,50
Stock Option (right to buy)	\$ 15.82	11/12/2015	M(1)	25,000	06/02/2011(10)	06/02/2020	Common Stock	25,00
Stock Option (right to buy)	\$ 9.3	11/11/2015	M(1)	25,000	06/09/2012(10)	06/09/2021	Common Stock	25,00

Reporting Owners

Reporting Owner Name / Address	Relationships						
r g	Director	10% Owner	Officer	Other			
STARR KEVIN P							
300 THIRD STREET	X						
CAMBRIDGE, MA 02142							

Signatures

By: /s/ Michael P. Mason, Attorney-In-Fact For: Kevin P. Starr 11/13/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2015.
- (2) Sale prices ranged from \$104.85 to \$105.70.
- (3) Sale prices ranged from \$105.86 to \$106.85.
- (4) Sale prices ranged from \$106.88 to \$107.875.
- (5) Sale prices ranged from \$107.88 to \$108.81.
- (6) Sale prices ranged from \$108.92 to \$109.62.
- (7) Sale prices ranged from \$100.00 to \$100.85.
- (8) Sale prices ranged from \$101.02 to \$101.92.
- (9) Sale prices ranged from \$102.67 to \$103.44.
- (10) The option vested, in full, on the first anniversary of the Grant Date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3